← Back
$APUS All transactions

Apimeds Pharmaceuticals US, Inc.

▲ BUY
9 / 10

Conviction

$ Value

$14K

Shares

7,730

Price

$2

Filed

May 15

Why this score? (9/10)
  • Open market buy (+3)
  • % of holdings >= 20% (+2)
  • Director (+1)
  • Cluster: 3 insiders buying (+2)
  • Not a 10b5-1 plan (+1)

Insider

Name

Kim Christopher

Title

Chairman and CMO

CIK

0002040022

Roles

Director Officer

Transaction Details

Transaction Date

2025-05-14

Code

P

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

27,500

Footnotes

The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2)-(3) to this Form 4. | These shares were sold in multiple transactions at prices ranging from $1.75 to $1.86, inclusive. | These shares were sold in multiple transactions at prices ranging from $1.84 to $1.89, inclusive.

Filing Info

Accession No.

0001474506-25-000096

Form Type

4

Issuer CIK

0001894525

Kim Christopher's History

Date Ticker Type Value
2025-10-15 APUS A $0
2025-05-16 APUS A $0
2025-05-14 APUS $14K
2025-05-13 APUS $36K

Other Insiders at APUS (90d)

No other insider activity at this issuer in the last 90 days.